Basilea Pharmaceutica AG

<!-- Name:DistributionId Value:1000782455 --> <!-- Name:NewsArchiveTags Value:AdHoc --> <!-- Name:NewsArchiveOrgTags Value:MyWeb#My…

<!-- Name:DistributionId Value:1000781180 --> <!-- Name:NewsArchiveTags Value:MyWeb --> <!-- Name:NewsArchiveOrgTags Value:MyWeb#My…

Continued commercial success of Cresemba and Zevtera in 2022 generated revenue contributions of approx. CHF 122 million, exceeding guidance by more than 17%Significant proceeds from oncology transactionsFollowing pre-NDA (New Drug…

Basel/Allschwil, Switzerland, December 28, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today…

Japanese regulatory authority granted marketing authorization to Basilea’s license partner, Asahi Kasei PharmaIntravenous and oral use of Cresemba approved for the treatment of adult patients with aspergillosis, mucormycosis, and…